ACETO Corp (ACET) Appoints Michael G. Kauffman to its Board

November 18, 2021 7:06 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.

"Dr. Kauffman’s appointment brings a wealth of expertise to our board and will be invaluable as we advance the development of our pipeline of next-generation off-the-shelf, gamma-delta CAR-T therapies," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Kauffman is an industry veteran with considerable experience in oncology drug development and, notably, has been instrumental in the approval of several oncology drugs. We look forward to benefiting from Michael’s expertise and insights."

Dr. Kauffman joins the Adicet board with over 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development and regulatory strategy. Currently, he is a board member for Karyopharm Therapeutics, Verastem Oncology and Kezar Life Sciences. Most recently, Dr. Kauffman served as the co-founder and Chief Executive Officer of Karyopharm, where he guided the Company’s transition from a discovery stage biotechnology company to a commercial stage organization. Prior to joining Karyopharm, Dr. Kauffman was Chief Medical Officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. Previously, Dr. Kauffman was President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals, and has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School and is board certified in Internal Medicine.

“Adicet’s leading gamma delta CAR-T cell platform is unique in that it is designed to leverage the inherent innate and adaptive ability of gamma delta T cells to complement a chimeric antigen receptor for enhanced tumor killing,” said Dr. Kauffman. “If successful in the clinic, these three anti-tumor mechanisms could provide significant benefits over current cell therapy platforms, without the need for gene editing. I look forward to working closely with the team to advance Adicet’s pipeline of off-the-shelf, CAR-T therapies for the treatment of cancer and other diseases.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Board Changes, Corporate News

Related Entities